The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: A European expert recommendation

Oliver Schnell, Hasan Alawi, Tadej Battelino, Antonio Ceriello, Peter Diem, Anne Marie Felton, Wladyslaw Grzeszczak, Kari Harno, P. Kempler, Ilhan Satman, Bruno Verges̀

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The role of glucagon-like peptide (GLP)-1-based treatment approaches for type 2 diabetes mellitus (T2DM) is increasing. Although self-monitoring of blood glucose (SMBG) has been performed in numerous studies on GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, the potential role of SMBG in GLP-1-based treatment strategies has not been elaborated. The expert recommendation suggests individualized SMBG strategies in GLP-1-based treatment approaches and suggests simple and clinically applicable SMBG schemes. Potential benefits of SMBG in GLP-1-based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and diabetes education. Its length and frequency should depend on the clinical setting and the quality of metabolic control. It is considered to play an important role for the optimization of diabetes management in T2DM patients treated with GLP-1-based approaches.

Original languageEnglish
Pages (from-to)665-673
Number of pages9
JournalJournal of diabetes science and technology
Volume6
Issue number3
DOIs
Publication statusPublished - 2012

Fingerprint

Blood Glucose Self-Monitoring
Glucagon-Like Peptide 1
Peptides
Glucose
Blood Glucose
Medical problems
Blood
Monitoring
Type 2 Diabetes Mellitus
Therapeutics
Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Quality Control
Education

Keywords

  • Diabetes
  • Dipeptidyl peptidase-4 inhibitors
  • Glucagon-like peptide-1 analogs
  • Hypoglycemia
  • Self-monitoring
  • Treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Bioengineering
  • Biomedical Engineering

Cite this

The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches : A European expert recommendation. / Schnell, Oliver; Alawi, Hasan; Battelino, Tadej; Ceriello, Antonio; Diem, Peter; Felton, Anne Marie; Grzeszczak, Wladyslaw; Harno, Kari; Kempler, P.; Satman, Ilhan; Verges̀, Bruno.

In: Journal of diabetes science and technology, Vol. 6, No. 3, 2012, p. 665-673.

Research output: Contribution to journalArticle

Schnell, O, Alawi, H, Battelino, T, Ceriello, A, Diem, P, Felton, AM, Grzeszczak, W, Harno, K, Kempler, P, Satman, I & Verges̀, B 2012, 'The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: A European expert recommendation', Journal of diabetes science and technology, vol. 6, no. 3, pp. 665-673. https://doi.org/10.1177/193229681200600323
Schnell, Oliver ; Alawi, Hasan ; Battelino, Tadej ; Ceriello, Antonio ; Diem, Peter ; Felton, Anne Marie ; Grzeszczak, Wladyslaw ; Harno, Kari ; Kempler, P. ; Satman, Ilhan ; Verges̀, Bruno. / The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches : A European expert recommendation. In: Journal of diabetes science and technology. 2012 ; Vol. 6, No. 3. pp. 665-673.
@article{c6448afd7e44437abbbd331d8a2fde91,
title = "The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: A European expert recommendation",
abstract = "The role of glucagon-like peptide (GLP)-1-based treatment approaches for type 2 diabetes mellitus (T2DM) is increasing. Although self-monitoring of blood glucose (SMBG) has been performed in numerous studies on GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, the potential role of SMBG in GLP-1-based treatment strategies has not been elaborated. The expert recommendation suggests individualized SMBG strategies in GLP-1-based treatment approaches and suggests simple and clinically applicable SMBG schemes. Potential benefits of SMBG in GLP-1-based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and diabetes education. Its length and frequency should depend on the clinical setting and the quality of metabolic control. It is considered to play an important role for the optimization of diabetes management in T2DM patients treated with GLP-1-based approaches.",
keywords = "Diabetes, Dipeptidyl peptidase-4 inhibitors, Glucagon-like peptide-1 analogs, Hypoglycemia, Self-monitoring, Treatment",
author = "Oliver Schnell and Hasan Alawi and Tadej Battelino and Antonio Ceriello and Peter Diem and Felton, {Anne Marie} and Wladyslaw Grzeszczak and Kari Harno and P. Kempler and Ilhan Satman and Bruno Verges̀",
year = "2012",
doi = "10.1177/193229681200600323",
language = "English",
volume = "6",
pages = "665--673",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "3",

}

TY - JOUR

T1 - The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches

T2 - A European expert recommendation

AU - Schnell, Oliver

AU - Alawi, Hasan

AU - Battelino, Tadej

AU - Ceriello, Antonio

AU - Diem, Peter

AU - Felton, Anne Marie

AU - Grzeszczak, Wladyslaw

AU - Harno, Kari

AU - Kempler, P.

AU - Satman, Ilhan

AU - Verges̀, Bruno

PY - 2012

Y1 - 2012

N2 - The role of glucagon-like peptide (GLP)-1-based treatment approaches for type 2 diabetes mellitus (T2DM) is increasing. Although self-monitoring of blood glucose (SMBG) has been performed in numerous studies on GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, the potential role of SMBG in GLP-1-based treatment strategies has not been elaborated. The expert recommendation suggests individualized SMBG strategies in GLP-1-based treatment approaches and suggests simple and clinically applicable SMBG schemes. Potential benefits of SMBG in GLP-1-based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and diabetes education. Its length and frequency should depend on the clinical setting and the quality of metabolic control. It is considered to play an important role for the optimization of diabetes management in T2DM patients treated with GLP-1-based approaches.

AB - The role of glucagon-like peptide (GLP)-1-based treatment approaches for type 2 diabetes mellitus (T2DM) is increasing. Although self-monitoring of blood glucose (SMBG) has been performed in numerous studies on GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, the potential role of SMBG in GLP-1-based treatment strategies has not been elaborated. The expert recommendation suggests individualized SMBG strategies in GLP-1-based treatment approaches and suggests simple and clinically applicable SMBG schemes. Potential benefits of SMBG in GLP-1-based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and diabetes education. Its length and frequency should depend on the clinical setting and the quality of metabolic control. It is considered to play an important role for the optimization of diabetes management in T2DM patients treated with GLP-1-based approaches.

KW - Diabetes

KW - Dipeptidyl peptidase-4 inhibitors

KW - Glucagon-like peptide-1 analogs

KW - Hypoglycemia

KW - Self-monitoring

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84878141828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878141828&partnerID=8YFLogxK

U2 - 10.1177/193229681200600323

DO - 10.1177/193229681200600323

M3 - Article

C2 - 22768899

AN - SCOPUS:84878141828

VL - 6

SP - 665

EP - 673

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 3

ER -